Macrocyclics Inc. is a specialist manufacturer of bespoke chelating agents and a provider of cGMP contract manufacturing services for the nuclear medicine and radiopharmaceutical sectors.

Founded in 1995 by Professor A. Dean Sherry, Macrocyclics emerged from pioneering academic research on macrocyclic ligands for diagnostic imaging and quickly evolved into a commercial enterprise. The company develops and supplies advanced chelation chemistry platforms tailored to both diagnostic and therapeutic applications in nuclear medicine. As of 2004, it has expanded to include fully GMP‑compliant manufacturing, supporting clinical programmes under its cGMP services

Now part of the Orano Med group, Macrocyclics operates from a state‑of‑the‑art facility in Plano, Texas, with dedicated chemistry, radiochemistry and analytical labs.

Key Products and Services

Bifunctional Chelators (BFCs) – A comprehensive range of metal‑binding ligands for conjugation to antibodies, peptides or small molecules.

Macrocyclic Ligands – High‑purity macrocycles such as DOTA and DO2A for imaging and therapeutic applications.

Fluorescent Probes & Magnetic Resonance Reagents – Ready‑to‑use reagents for preclinical and imaging research.

Reactive Intermediates & Conjugates – Custom intermediates to support complex molecule assembly.

cGMP Services – GMP manufacturing of custom chelators and intermediates for clinical use.

Peptide Synthesis & Bioconjugation – In‑house peptide production and conjugation expertise underpinned by advanced radiochemistry lab facilities.

Analytical Testing & Consulting – Full support in analytical development, quality assurance and scientific consulting.

With over 25 years of experience and a robust product portfolio, Macrocyclics positions itself as a leading partner to academia, biotech and pharmaceutical clients in molecular imaging and radiotherapy. Its integration within the Orano Med group and comprehensive GMP capabilities further reinforce its capacity to enable early‑stage clinical and commercial development of radiopharmaceuticals worldwide.